Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Geron Corporation
< Previous
1
2
3
4
Next >
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 22, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
August 08, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
July 23, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
June 06, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
May 02, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
April 25, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Participate at Upcoming Investor Conferences in April
April 03, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
March 19, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
March 14, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 22, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
January 12, 2024
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
December 11, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
December 06, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
December 04, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
November 28, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Participate at Upcoming Investor Conferences in November
November 07, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
November 02, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
November 02, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
October 26, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 19, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
September 29, 2023
From
Geron Corporation
Via
Business Wire
Tickers
GERN
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.